Be Preventative, Go Regenerative
Axolotl Biologix is focused on science and research to uncover optimal enablement of the body’s own cells to create evidence-based clinical protocols. We profile the company to learn more about the unique work it undertakes in this vital area and how it works towards changing the health of the world’s population for the better while lowering patient costs.
Since its inception in 2016, Axolotl Biologix’ mission has been to improve the quality of life for people around the world. Axolotl Biologix is committed to acting as an innovative leader of regenerative medicine through research, technology, and clinical application.
Through science and research, the firm’s dedicated team is looking to create better products that physicians can use to provide better care for patients. To achieve this, the firm is committed to evidence-based protocols and collecting data on patient outcomes.
As part of its commitment to changing lives for the better, Axolotl’s number one priority is patient safety, and as such the firm closely follow the U.S. Food and Drug Administration’s (FDA) Current Good Tissue Practices (CGTP) to meet and exceed standards. The firm has an established quality program with fully documented procedures and trained staff to ensure that at every stage of research, manufacturing, and treatment, patients safety is first and foremost.
Currently, the firm is generating revenue through three products, and as has two exclusive, worldwide licenses to two U.S. patents using Tropoelastin in medical applications. The first product using Tropoelastin that is under current development is an extracellular matrix (ECM). The next three products using the biomaterial is a surgical mesh, a cardiac patch, and an electrospun blood vessel that has elasticity and tensile strength. Elastin is the structural protein that provides tissues with their ability to stretch and recoil and is most prevalent, and essential, in organs that expand and contract. Elastin in its hydrolyzed form has been made available historically when isolated from animals, but the resulting inert material has little value for engineered tissue applications.
Tropoelastin is the natural high molecular weight (70kDA) precursor to elastin. Research and development on Tropoelastin in based polymer materials has been very limited to date to a small group of academics and one Australian start up with no significant corporate support.
Axolotl Biologix, through an exclusive license with Protein Genomics, has the developed know-how, proprietary information and patents to develop Tropoelastin based polymers for clinical applications. No other company in the world can use Tropoelastin in medical applications, offering Axolotl Biologix a unique advantage.
Today the firm markets three products utilizing this innovative technology, AxoBioFluid’C (Cryopreserved), AxoBioFluid’A (Ambient), and AxoBioMembrane’, all of which are classified as minimally manipulated under FDA regulation 21 CFR Part 1271 and section 361 of the PHS.
AxoBioFluid’ is available in two forms. The first product is a cryopreserved liquid allograft derived from the placental components of the amnion to advance soft tissue repair, replacement, and reconstruction. The second product is the same AxoBioFluid’ and available in an ambient (room temperature) form, which allows for a two-year shelf life.
Finally, AxoBioMembrane’ is a dehydrated human amnion membrane (dHAM) allograft and is composed primarily of a connective tissue matrix. It is minimally manipulated and provides the extracellular matrix and associated growth factors and cytokines that are normally present in amniotic tissue. The presence of the connective tissue matrix and associated factors help to regenerate soft tissue while inhibiting inflammation and scar tissue formation. Alongside its current projects, Axolotl Biologix has five products on the firm’s product roadmap today to help it build upon its current success and support even more patients around the world.
Ultimately, Axolotl believes that greater levels of regeneration exist within our own bodies and that over time research will uncover this and lead to the development of innovative technologies that will allow humans to achieve what the Axolotl, a unique regenerating amphibian, already has. The company’s overall goal is to become a global leader in regenerative medicine through research, technology, and clinical application. As such, more discoveries and greater research into the area of regeneration will remain the firm’s ongoing focus as it seeks to achieve what these ambitious salamanders already have.
Company: Axolotl Biologix
Contact: Bob Maguire
Email: [email protected]
Address: 1637 West Knudsen Drive, Phoenix, AZ, 85027, USA
Phone: 001 602 354 3081
Website: https://www.axobio.com
